PE-22-28

Overview

PE-22-28 is a synthetic heptapeptide — a chain of seven amino acids (sequence GVSWGLR) — derived from spadin, a naturally occurring peptide released during the maturation of the sortilin protein. It is studied primarily as a research tool for exploring the TREK-1 potassium channel and its role in mood regulation.

Interest in PE-22-28 comes largely from depression research. In preclinical work it has been described as the shortest active fragment of spadin, retaining similar channel-blocking activity in a much smaller, more stable molecule. Researchers have reported that it is considerably more potent than full-length spadin at its target.

The evidence base is early. Findings to date come from rodent and cell-culture studies, and PE-22-28 is not approved by any major regulator for therapeutic use. There are no completed, published human efficacy trials.

How it works

PE-22-28 acts as a selective blocker of the TREK-1 (KCNK2) channel, a two-pore-domain potassium channel found in neurons of the hippocampus, cortex, and dorsal raphe. By inhibiting this channel, it is thought to alter neuronal excitability in circuits relevant to mood, and preclinical studies have linked TREK-1 blockade to rapid antidepressant-like signaling.

In rodent models, spadin-derived peptides including PE-22-28 have also been reported to enhance hippocampal neurogenesis and serotonergic activity — markers commonly associated with antidepressant response. The precise mechanism and relevance in humans have not been established.

Reported benefits

• Rapid antidepressant-like effects in rodent behavioral models (preclinical)
• Enhanced hippocampal neurogenesis and synaptogenesis in animal studies
• Selective TREK-1 channel inhibition used as a research tool for mood pathways

These are reported findings from early research, not guaranteed outcomes, and largely reflect animal and cell-based data.

Considerations & side effects

Because PE-22-28 has not been evaluated in published human trials, its safety profile in people is essentially uncharacterized, and long-term effects are unknown. It remains a preclinical research compound rather than an approved medication.

Product purity and identity vary widely in the research-chemical market, and material sold under this name is not manufactured to pharmaceutical standards. It is not a substitute for evaluation and treatment by a qualified clinician, and anyone experiencing depression or other mental-health symptoms should seek professional care.